Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAR-210 versus intravesical chemotherapy in FGFR-altered intermediate-risk non-muscle invasive bladder cancer
ISRCTN76448481Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2024
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of erdafitinib, mitomycin c and gemcitabine in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Disease-free survival. Started Apr 2024; status: active, not recruiting.
02
Drugs
erdafitinibmitomycin cgemcitabine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ISRCTN76448481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN76448481.